Literature DB >> 32451499

Systemic dysfunction and plasticity of the immune macroenvironment in cancer models.

Breanna M Allen1,2, Kamir J Hiam1,2, Cassandra E Burnett1,2, Anthony Venida1,3, Rachel DeBarge1,2, Iliana Tenvooren2, Diana M Marquez2, Nam Woo Cho2,4, Yaron Carmi5, Matthew H Spitzer6,7.   

Abstract

Understanding of the factors governing immune responses in cancer remains incomplete, limiting patient benefit. In this study, we used mass cytometry to define the systemic immune landscape in response to tumor development across five tissues in eight mouse tumor models. Systemic immunity was dramatically altered across models and time, with consistent findings in the peripheral blood of patients with breast cancer. Changes in peripheral tissues differed from those in the tumor microenvironment. Mice with tumor-experienced immune systems mounted dampened responses to orthogonal challenges, including reduced T cell activation during viral or bacterial infection. Antigen-presenting cells (APCs) mounted weaker responses in this context, whereas promoting APC activation rescued T cell activity. Systemic immune changes were reversed with surgical tumor resection, and many were prevented by interleukin-1 or granulocyte colony-stimulating factor blockade, revealing remarkable plasticity in the systemic immune state. These results demonstrate that tumor development dynamically reshapes the composition and function of the immune macroenvironment.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32451499      PMCID: PMC7384250          DOI: 10.1038/s41591-020-0892-6

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  49 in total

1.  Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity.

Authors:  Kenji Chamoto; Partha S Chowdhury; Alok Kumar; Kazuhiro Sonomura; Fumihiko Matsuda; Sidonia Fagarasan; Tasuku Honjo
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-17       Impact factor: 11.205

2.  Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM.

Authors:  Dimitrios Mathios; Jennifer E Kim; Antonella Mangraviti; Jillian Phallen; Chul-Kee Park; Christopher M Jackson; Tomas Garzon-Muvdi; Eileen Kim; Debebe Theodros; Magdalena Polanczyk; Allison M Martin; Ian Suk; Xiaobu Ye; Betty Tyler; Chetan Bettegowda; Henry Brem; Drew M Pardoll; Michael Lim
Journal:  Sci Transl Med       Date:  2016-12-21       Impact factor: 17.956

3.  Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity.

Authors:  Tyler J Curiel; Shuang Wei; Haidong Dong; Xavier Alvarez; Pui Cheng; Peter Mottram; Roman Krzysiek; Keith L Knutson; Ben Daniel; Maria Carla Zimmermann; Odile David; Matthew Burow; Alan Gordon; Nina Dhurandhar; Leann Myers; Ruth Berggren; Akseli Hemminki; Ronald D Alvarez; Dominique Emilie; David T Curiel; Lieping Chen; Weiping Zou
Journal:  Nat Med       Date:  2003-04-21       Impact factor: 53.440

4.  Systemic Immunity Is Required for Effective Cancer Immunotherapy.

Authors:  Matthew H Spitzer; Yaron Carmi; Nathan E Reticker-Flynn; Serena S Kwek; Deepthi Madhireddy; Maria M Martins; Pier Federico Gherardini; Tyler R Prestwood; Jonathan Chabon; Sean C Bendall; Lawrence Fong; Garry P Nolan; Edgar G Engleman
Journal:  Cell       Date:  2017-01-19       Impact factor: 41.582

Review 5.  The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis.

Authors:  Sandra S McAllister; Robert A Weinberg
Journal:  Nat Cell Biol       Date:  2014-08       Impact factor: 28.824

6.  Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression.

Authors:  Heng Lin; Shuang Wei; Elaine M Hurt; Michael D Green; Lili Zhao; Linda Vatan; Wojciech Szeliga; Ronald Herbst; Paul W Harms; Leslie A Fecher; Pankaj Vats; Arul M Chinnaiyan; Christopher D Lao; Theodore S Lawrence; Max Wicha; Junzo Hamanishi; Masaki Mandai; Ilona Kryczek; Weiping Zou
Journal:  J Clin Invest       Date:  2018-01-16       Impact factor: 14.808

7.  PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression.

Authors:  Haidong Tang; Yong Liang; Robert A Anders; Janis M Taube; Xiangyan Qiu; Aditi Mulgaonkar; Xin Liu; Susan M Harrington; Jingya Guo; Yangchun Xin; Yahong Xiong; Kien Nham; William Silvers; Guiyang Hao; Xiankai Sun; Mingyi Chen; Raquibul Hannan; Jian Qiao; Haidong Dong; Hua Peng; Yang-Xin Fu
Journal:  J Clin Invest       Date:  2018-01-16       Impact factor: 14.808

8.  The Role of Myeloid-Derived Suppressor Cells in Patients with Solid Tumors: A Meta-Analysis.

Authors:  Shuo Zhang; Xuelei Ma; Chenjing Zhu; Li Liu; Guoping Wang; Xia Yuan
Journal:  PLoS One       Date:  2016-10-25       Impact factor: 3.240

9.  Clonal replacement of tumor-specific T cells following PD-1 blockade.

Authors:  Kathryn E Yost; Ansuman T Satpathy; Daniel K Wells; Yanyan Qi; Chunlin Wang; Robin Kageyama; Katherine L McNamara; Jeffrey M Granja; Kavita Y Sarin; Ryanne A Brown; Rohit K Gupta; Christina Curtis; Samantha L Bucktrout; Mark M Davis; Anne Lynn S Chang; Howard Y Chang
Journal:  Nat Med       Date:  2019-07-29       Impact factor: 53.440

10.  Chromatin states define tumour-specific T cell dysfunction and reprogramming.

Authors:  Mary Philip; Lauren Fairchild; Liping Sun; Ellen L Horste; Steven Camara; Mojdeh Shakiba; Andrew C Scott; Agnes Viale; Peter Lauer; Taha Merghoub; Matthew D Hellmann; Jedd D Wolchok; Christina S Leslie; Andrea Schietinger
Journal:  Nature       Date:  2017-05-17       Impact factor: 49.962

View more
  51 in total

1.  SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery.

Authors:  Siwen Hu-Lieskovan; Srabani Bhaumik; Kavita Dhodapkar; Jean-Charles J B Grivel; Sumati Gupta; Brent A Hanks; Sylvia Janetzki; Thomas O Kleen; Yoshinobu Koguchi; Amanda W Lund; Cristina Maccalli; Yolanda D Mahnke; Ruslan D Novosiadly; Senthamil R Selvan; Tasha Sims; Yingdong Zhao; Holden T Maecker
Journal:  J Immunother Cancer       Date:  2020-12       Impact factor: 13.751

Review 2.  Tumor-draining lymph nodes: At the crossroads of metastasis and immunity.

Authors:  Haley du Bois; Taylor A Heim; Amanda W Lund
Journal:  Sci Immunol       Date:  2021-09-03

Review 3.  Signal pathways of melanoma and targeted therapy.

Authors:  Weinan Guo; Huina Wang; Chunying Li
Journal:  Signal Transduct Target Ther       Date:  2021-12-20

Review 4.  Myelopoiesis during Solid Cancers and Strategies for Immunotherapy.

Authors:  Tyler J Wildes; Bayli DiVita Dean; Catherine T Flores
Journal:  Cells       Date:  2021-04-21       Impact factor: 6.600

Review 5.  Engineered models of tumor metastasis with immune cell contributions.

Authors:  Pamela L Graney; Daniel Naveed Tavakol; Alan Chramiec; Kacey Ronaldson-Bouchard; Gordana Vunjak-Novakovic
Journal:  iScience       Date:  2021-02-12

6.  Breast cancer-derived GM-CSF regulates arginase 1 in myeloid cells to promote an immunosuppressive microenvironment.

Authors:  Xinming Su; Yalin Xu; Gregory C Fox; Jingyu Xiang; Kristin A Kwakwa; Jennifer L Davis; Jad I Belle; Wen-Chih Lee; Wing H Wong; Francesca Fontana; Leonel F Hernandez-Aya; Takayuki Kobayashi; Helen M Tomasson; Junyi Su; Suzanne J Bakewell; Sheila A Stewart; Christopher Egbulefu; Partha Karmakar; Melisa A Meyer; Deborah J Veis; David G DeNardo; Gregory M Lanza; Samuel Achilefu; Katherine N Weilbaecher
Journal:  J Clin Invest       Date:  2021-10-15       Impact factor: 14.808

7.  Solid stress impairs lymphocyte infiltration into lymph-node metastases.

Authors:  Dennis Jones; Zixiong Wang; Ivy X Chen; Sue Zhang; Rohin Banerji; Pin-Ji Lei; Hengbo Zhou; Victoria Xiao; Cecilia Kwong; Jan Willem M van Wijnbergen; Ethel R Pereira; Benjamin J Vakoc; Peigen Huang; Hadi T Nia; Timothy P Padera
Journal:  Nat Biomed Eng       Date:  2021-07-19       Impact factor: 25.671

Review 8.  The Liver-Immunity Nexus and Cancer Immunotherapy.

Authors:  James C Lee; Michael D Green; Laura A Huppert; Christine Chow; Robert H Pierce; Adil I Daud
Journal:  Clin Cancer Res       Date:  2021-07-20       Impact factor: 12.531

Review 9.  Divergent Sepsis Pathophysiology in Older Adults.

Authors:  Meagan S Kingren; Marlene E Starr; Hiroshi Saito
Journal:  Antioxid Redox Signal       Date:  2021-10-01       Impact factor: 8.401

Review 10.  Leveraging microenvironmental synthetic lethalities to treat cancer.

Authors:  Kevin J Metcalf; Alaa Alazzeh; Zena Werb; Valerie M Weaver
Journal:  J Clin Invest       Date:  2021-03-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.